3i
Deutschland 3i brings capital, knowledge and connections to the creation and development of businesses around the world. It invests in a wide range of opportunities from start-ups to buy-outs and buy-ins, focusing on businesses with high growth potential and strong management. 3i invests in businesses across three continents through local investment teams in Europe, Asia Pacific and the USA. To date, 3i has invested over £14.5 billion (including co-investment funds). In the 12 months to 31 March 2002, an average
of £4.1 million (including co-investment funds) was invested
each working day. |
 |
| Apax
Partners Apax Partners is one of the world's leading private equity investment groups dedicated to high performance, entrepreneurial businesses. The group advises a number of Investment Pools with an accumulated total of € 12 billion and pursues a balanced equity portfolio strategy, investing in companies at all stages of development from start-up to buy-out. The group focuses primarily on six industry sectors: Telecommunications, Information Technologies, Media, Healthcare & Biotechnologies, Retail & Consumer Products and Financial Services. Founded in 1972 in the United States and in Europe, Apax Partners currently has eleven offices worldwide. |
 |
Atlas Venture Founded in 1980, Atlas Venture has organized six international funds, and currently manages over $2.4 billion in committed capital. The Atlas Venture investment team is comprised of seasoned operating executives and career venture capitalists who have been deeply involved in the formation and development of more than 300 companies worldwide. Atlas Venture is the leading international, early-stage venture capital firm investing in communications technology, information technology and life sciences companies. With offices in Amsterdam, Boston, London, Menlo Park, Munich, Paris, and Seattle, Atlas Venture’s investments are split evenly between the United States and Europe. In 2000, our portfolio completed 14 IPOs and 11 acquisitions. Recent Atlas Venture portfolio company IPOs include Actelion (SWX: ATLN), deCODE genetics (Nasdaq: DCGN), Exelixis (Nasdaq: EXEL), Orchestream Ltd (LSE: OCH), SpeechWorks International (Nasdaq: SPWX) and Variagenics (Nasdaq: VGNX). Recent acquisitions of Atlas Venture portfolio companies include Cerulean Technology (Aether Systems), eGroups (Yahoo!), OnDisplay (Vignette), Trading Dynamics (Ariba), Omnia Communications (CIENA), RightPoint Software (E.piphany), Element 14 (Broadcom) and T.sqware (GlobeSpan). |
|
BankInvest Bio
Venture BankInvest was established as a mutual fund in 1969 by a number of local and regional banks, and today's owners represent a total balance of more than 35bn euros. With more than 30 years' experience as an asset management company and with more than 100,000 unit holders, institutional investors and corporations as clients, BankInvest is at present Denmark's third largest mutual fund manager and advisor. In June 2001, BankInvest's assets under management amounted to approximately 5bn euros, and these continue to grow extremely strongly. BankInvest manages portfolios of both bonds and equities. By using a selective investment strategy, BankInvest manages portfolios with focus on geographic areas as well as sector-specific portfolios. It is particularly within the fields of complex investments, e.g. biotechnology, information technology and emerging markets, that BankInvest distinguishes itself as an internationally leading asset management group. In the field of venture capital, BankInvest is also one of the leading venture capital providers in Denmark within the growth areas of biotechnology and information technology |
 |
Earlybird Venture
Capital GmbH & Co KG Earlybird provides capital, know-how, management support and a large network of industry experts to selected European and North American new technology enterprises and innovative entrepreneurs. Its strategy is to be among the first venture investors in technology companies that seek to create new markets. Earlybird currently manages three funds totalling US $ / Euro 300 million in committed capital. Its investment focus lies on information technology, communications, healthcare and convergent technologies. With offices in Europe (Hamburg, Munich) and the US (Palo Alto), Earlybird is well positioned to take advantage of international opportunities and to assist its portfolio companies to gain access to the international market place and financial resources. Earlybird’s investment professionals have extensive finance and start-up operating experience and actively support portfolio companies. In addition, a network of experienced industry specialists serves on the advisory board and assists Earlybird and its portfolio companies in providing strategic advice and operational support. |
 |
GlaxoSmithKline GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer. Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. GSK has leadership in four major of the five major therapeutic areas - anti-infectives, central nervous system, respiratory and gastrointestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products. The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders. |
 |
HBM Partners AG HBM BioVentures Ltd. is a holding company established under Swiss law, domiciled in Baar, Switzerland. The company invests primarily in later-stage private equity, but also in publicly traded companies in the biotechnology, emerging pharmaceutical, medical technology and related industries. Portfolio companies are located mainly in Western Europe and the U.S. While most investments are made in companies directly, some take place through specialised, regional earlystage investment vehicles. Within its industrial scope HBM BioVentures is unique in that it offers institutional and private investors an ideal opportunity to invest in a broadly diversified portfolio combining private and public companies. HBM BioVentures is independent and offers a flexible investment vehicle as a platform for active financial engineering. It is managed by investment professionals and combines high transparency with an advantageous tax structure. |
|
Imperial College
of Science, Technology & Medicine Company Profile to follow shortly. |
 |
Karolinska Innovations
AB Karolinska Innovations (KIAB) invests in promising inventions at Karolinska Institutet. KIAB invests in and manages the first steps of commercial development of academic research results towards innovative new products and therapies for the consumer market. During last two years KIAB has formed and found external investors to 10 new biotech companies and has also closed 10 license deals with companies in the international Pharmaceutical & Biotech industry. Karolinska Innovations AB is a fully-owned subsidiary of Karolinska Institutet Holding AB. |
 |
Katan Associates Katan is a globally based advisory services organization that provides a variety of integrated and interdisciplinary business and financial services to developing, knowledge-based growth and biotechnology companies. Our clients will share in the diversified operational, financial and strategic experiences that Katan’s senior management has gained in their various roles with numerous companies. We have a proven track record of adding significant value to formative-stage companies, providing management, financial, business development and strategic basis for a company’s growth and success. Katan assists in any of the following areas:
|
 |
Merlin Biosciences Merlin Biosciences, founded in 1996, is a specialised venture capital and advisory company dedicated to the life sciences sector. Merlin has one of the largest, most experienced biotech investment teams in Europe and is currently advising funds approaching € (Euro) 400 million and has an extensive network of advisers and experienced strategic partners. Merlin supports companies in all stages of their development - from start-up, through pre-IPO and post-flotation. Merlin advises three funds which encompass this full spectrum of development: The Merlin Biosciences Fund, the Merlin Fund and the Finsbury Life Sciences Investment Trust (FLIT). |
 |
MPM Capital MPM Capital L.P. is a global asset management firm focused solely on healthcare investing from early stage start-ups to large capitalization public companies. Headquartered in Boston, Massachusetts, MPM Capital has offices in South San Francisco, California and Munich, Germany. MPM’s current portfolio consists of biopharmaceutical and medical devices companies and encompasses platform technology as well as product plays. The firm has over $1.9 billion in assets under management through $1.5 billion in the MPM BioVentures family of venture capital funds and $400 million in MPM BioEquities, a fund investing in public healthcare companies. These combined funds make MPM Capital one of the largest asset management firms dedicated to the life sciences sector. |
 |
NMT Management
AG NMT New Medical Technologies is a venture partner
investing in innovative medical and healthcare technologies and
services. NMT seeks investment opportunities in breakthrough biopharmaceutical and medical technologies from universities and other private entities as well as spin-offs from large corporations. NMT also makes carefully timed, value-driven investments in existing late stage and promising small capitalized public companies on a worldwide basis, especially in the USA. Furthermore, NMT attracts selected overseas start-ups, early- and late-stage companies to the Alpine Rim supporting them in technology bundling and building up European operations as well as in going public. The Company was founded in 1997 by Roche, UBS and a small group of private investors. Since the latest capital increase of December 2000, NMT operates with a committed capital of nearly CHF 300 million. email: office@nmt.ch |
 |
Oxford Bioscience
Partners Oxford Bioscience Partners (OBP) is a life science venture capital firm that provides equity financing and management assistance to start-up and early-stage, entrepreneurial-driven companies in the bioscience and healthcare industries. The General Partners of OBP currently manage venture funds with combined committed capital of more than $800 million. |
 |
Serono
International S.A. Serono is a global biotechnology leader. The Company has six recombinant products on the market, Gonal-F®, Luveris®,m Ovidrel®/Ovitrelle®, Rebif®, Serostim® and Saizen® (Rebif® and Luveris® are not approved in the USA). In addition to being the world leader in reproductive health, Serono has strong market positions in neurology, metabolism and growth. The Company’s research programs are focused on growing these businesses and on establishing new therapeutic areas. Currently, there are fifteen new molecules in development. In 2000, Serono achieved worldwide revenues of US$1.240 billion, and a net income of US$301 million, making it the third largest biotech company in the world based on revenues. The Company operates in 45 countries, and its products are sold in over 100 countries. Bearer shares of Serono S.A., the holding company, are traded on the SWX Swiss Exchange (SEO) and its American Depositary Shares are traded on the New York Stock Exchange (SRA). |
 |
| Sofinnova Partners
Sofinnova Partners, based in Paris since 1972, is a leading European venture capital firm dedicated to financing and building early stage information technology and life sciences companies in Europe and the US. Sofinnova Partners has in total over €500M under management. In the past five years, Sofinnova Partners has made over 60 investments, primarily as lead or co-lead investor. In the life sciences, these have been focused on biopharmaceutical and medical device companies such as Actelion, Nicox, Novuspharma, IDM and SpineVision. Sofinnova Partners’ most recent investments include: Biolipox (Sweden), David Pharmaceuticals (US), Cellzome (Germany), Faust Pharmaceuticals (France), Carex (France), Pro-Med (Austria), Addex Pharmaceuticals (Switzerland). |
Techno Venture
Management Techno Venture Management (TVM), founded in 1983, is one of the first venture capital funds formed in Germany, and a leader in transatlantic operations. The German-U.S. venture capital company has offices in Munich and Boston. For many years, TVM has focused on information technology and life sciences, high growth sectors where innovation, effective management and sound financial backing have enormous impact on company growth. TVM funds have made investments in 200 technology companies in Europe and the United States. A pivotal objective is to create transnational businesses that enjoy access to science, management talent and capital on both sides of the Atlantic. |
 |
Warburg
Pincus With over $10 billion under management and a further $5 billion available to invest, Warburg Pincus is among the largest private equity investment firms in the world. The firm has invested more than $12 billion in over 450 companies in 29 countries over the past 35 years. One of the world's leading direct equity investors in healthcare, Warburg Pincus has helped to build more than 35 biotechnology and biopharmaceuticals companies spanning a broad range of technologies and stages of development. |